NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Since the overall survival at five years for DCVax-l treated nGBM patients
was very similar for patients with significant residual disease as it was
for those with minimal residual disease, can we therefore speculate
that employment of temodar, even for methylated nGBM patients is
counterproductive because while somewhat reducing the tumor
load, temodar is likely to suppress the immunological response
capacity of DCVax-L.